Vaksin tungau debu rumah: Terobosan baru untuk mengatasi tantangan dermatitis atopik
DOI:
https://doi.org/10.25170/djm.v23i2.3830Keywords:
dermatitis atopik, vaksin, tungau debu rumahAbstract
Pendahuluan: Dermatitis atopik (DA) adalah penyakit inflamasi kronis yang sering dikaitkan dengan alergen tungau debu rumah (TDR), terutama Dermatophagoides pteronyssinus. Penatalaksanaan saat ini belum memadai untuk memberikan perlindungan jangka panjang.
Tujuan: Tinjauan ini bertujuan untuk mengeksplorasi potensi vaksin TDR sebagai terobosan baru dalam pengelolaan DA.
Metode: Artikel ini disusun melalui telaah literatur dari jurnal, buku, dan dokumen relevan lainnya yang membahas DA, imunoterapi, dan vaksinasi terkait. Data dianalisis secara komprehensif untuk mendukung kesimpulan.
Diskusi: Disfungsi sawar kulit dan respons imun yang dimediasi IgE adalah faktor utama dalam pathogenesis DA. Vaksinasi berbasis epitope TDR menawarkan peluang untuk pencegahan dengan efektivitas tinggi. Studi in sillico menunjukkan hasil menjanjikan, namun validasi lebih lanjut secara in vitro dan in vivo diperlukan. Pengembangan vaksin TDR multi-epitop dapat menjadi alternatif jangka panjang untuk DA.
Simpulan: Vaksinasi TDR memiliki potensi besar sebagai strategi pencegahan primer untuk DA, namun penelitian lebih lanjut masih dibutuhkan untuk penerapan klinis.
Downloads
References
Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. Atopic dermatitis. In: Fitzpatrick’s Dermatology. 9th ed. New York: McGraw-Hill; 2018. p. 363–84.
Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. The Journal of Immunology. 1923 May 1;8(3):163-82.
Rubel D, Thirumoorthy T, Soebaryo RW, Weng SCK, Gabriel TM, Villafuerte LL, et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013 Mar;40(3):160–71.
Keles FF, Pandaleke HE, Mawu FO. Profil derma-
titis atopik pada anak di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado periode Ja-nuari 2013 – Desember 2015. eCl. 2016 Jul 12;4(2).
Lee J, Lee H, Noh S, Bae BG, Shin JU, Park CO, et al. Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. Yonsei Med J. 2016;57(2):393.
Ferrando M, Bagnasco D, Passalacqua G, Varricchi G, Canonica GW. MK-8237: A house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. Expert Opinion on Biological Therapy. 2016 Nov;16(11):1435–41.
Palmer CNA, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006 Apr;38(4):441–6.
Pandaleke TA, Pandaleke HEJ. Etiopatogenesis dermatitis atopi. Jurnal Biomedik:JBM. 2014 Sep 11;6(2):76-83.
Badloe FMS, de Vriese S, Coolens K, Schmidt-Weber CB, Ring J, Gutermuth J, et al. IgE auto-antibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020 Aug 3;10(1):1–15.
Tham EH, Leung DYM. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res. 2019 Jan 1;11(1):4–15.
Wahongan GJ, Tulung M, Baskoro T, Satoto T, Sembel DT. Types and density of dust mites found among different habitats in houses in North Sulawesi Province, Indonesia. J Entomol Zool Stud. 2017;5(2):681–5.
Rizk P, Rodenas M, de Benedetto A. Allergen immunotherapy and atopic dermatitis: the Good, the bad, and the unknown. Curr Allergy Asthma Rep. 2019 Nov 27;19(12):57.
Ginsberg DN, Eichenfield LF. Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the "con" view. World Allergy Organ J. 2016 Apr 18;9:16.
Adji A, Niode NJ, Memah V v., Posangi J, Wahongan GJP, Ophinni Y, et al. Designing an epi-tope vaccine against Dermatophagoides pteronyssinus: An in silico study. Acta Trop. 2021 Oct 1;222.
Endaryanto A. Pengaruh dermatitis atopik, urtikaria dan gangguan saluran cerna sebagai komorbiditas dalam perbaikan klinis dan kepuasan orang tua pasien pada anak alergi dengan gejala saluran nafas tingkat moderate-persistent yang menda-patkan imunoterapi alergen debu rumah. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2019 Jul 31;31(2):112–22.
Pollard AJ, Bijker EM. A guide to vaccinology: from
basic principles to new developments. Nature Reviews Immunology. 2020 Dec 22;21(2):83–100.
Tang RB. House dust mite-specific immunotherapy alters the natural course of atopic march. J Chin Med Assoc. 2020 Feb;83(2):109-112.
Chruszcz M, Pomés A, Glesner J, Vailes LD, Osinski T, Porebski PJ, et al. Molecular determinants for antibody binding on group 1 house dust mite allergens. J Biol Chem. 2012 Mar 2;287(10): 7388–98.
Silny W, Czarnecka-Operacz M. Specific immunetherapy in the treatment of patients with atopic dermatitis. Rev Fr Allergol Immunol Clin. 1999;39(3 SUPPL. 1):69–71.
Lee J, Park CO, Lee KH. specific immunotherapy in atopic dermatitis. Allergy Asthma Immunol Res. 2015;7(3):221.
Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974 Jun;32(6):321-30.
Warmer JO, Soothill JF, Price JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978 Oct 28;2(8096):912–5.
Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22(4):440–6.
Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology. 2007 Jul;120(1):164–70.
Novak N, Bieber T, Hoffmann M, Fölster-Holst R, Homey B, Werfel T, Sager A, Zuberbier T. Efficacy and safety of subcutaneous allergen-specific immu-notherapy with depigmented polymerized mite ex-tract in atopic dermatitis. J Allergy Clin Immunol.
Oct;130(4):925-31.e4.
Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014;53(5):650-5.
Lee J, Lee H, Noh S, Bae BG, Shin JU, Park CO, et al. Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. Yonsei Med J [Internet]. 2016 Mar 1 [cited 2022 Sep 28];57(2):393–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26847292/
Zolkipli Z, Roberts G, Cornelius V, Clayton B, Pearson S, Michaelis L, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol. 2015 Dec 1;136(6):1541-1547.e11.
Liu L, Chen J, Xu J, Yang Q, Gu C, Ni C, et al. Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multicentre, randomized, double-blind, placebo-controlled study. Artif Cells Nanomed Biotechnol. 2019 Sep 28];47(1): 3540–7.
Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842–54.
Reginald K, Chew FT. Conformational IgE Epitope Mapping of Der p 2 and the evaluations of two candidate hypoallergens for immunotherapy. Scientific Reports 2018 8:1. 2018 Feb 21;8(1):1–8.
Anamika Basu, Anasua Sarkar, Piyali Basak. Epitope-based molecular docking studies of allergenic proteins with immunoglobulin protein during type I hypersensitivity reaction.
Basu A, Sarkar A, Basak P. Epitope-based molecular docking studies of allergenic proteins with immunoglobulin protein during type I hypersensitivity reaction. J Inn Pharm Bio Sci. 2017 Oct. 5;4(4):43-54
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Damianus Journal of Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
